Picture loading failed.

Anti-IL23A therapeutic antibody (Pre-made Tildrakizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Tildrakizumab (trade name Ilumya (US)/Ilumetri (European Union)) is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-573-1mg 1mg 3090
GMP-Bios-ab-573-10mg 10mg 21890
GMP-Bios-ab-573-100mg 100mg 148000
GMP-Bios-ab-573-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-IL23A therapeutic antibody (Pre-made Tildrakizumab biosimilar,Whole mAb)
INN Name Tildrakizumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesAlmirall S.A.;Merck & Co;Schering-Plough;Sun Pharmaceutical Industries
Conditions ApprovedPlaque psoriasis
Conditions ActiveAnkylosing spondylitis;Intervertebral disc degeneration;Non-radiographic axial spondyloarthritis;Psoriatic arthritis
Conditions DiscontinuedAutoimmune disorders
Development Techna